<DOC>
	<DOCNO>NCT01795339</DOCNO>
	<brief_summary>This two-part multiple dose study healthy male female ( non-child bearing potential ) elderly volunteer , Alzheimer 's disease patient , assess safety , effect body , blood , CSF , urine drug level AZD3293 . AZD3293 develop treatment Alzheimer 's Disease</brief_summary>
	<brief_title>A Two-part Multiple Dose Study Assess Safety Effects AZD3293 Healthy Elderly Alzheimer 's Patients</brief_title>
	<detailed_description>A Phase I , Randomized , Double-Blind , Placebo-Controlled , Two-Part , Multiple Ascending Dose Study Assess Safety , Tolerability , Pharmacokinetics Effect Biomarkers AZD3293 Plasma Cerebrospinal Fluid Healthy Male Non-Fertile Female Elderly Volunteers Mild-to-Moderate Alzheimer Disease Patients</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Part 1 : Healthy elderly male female ( nonchildbearing potential ) subject . Part 2 : Male nonfertile female AD patient . Body mass index ( BMI ) 19 30 kg/m2 weigh least 50 kg 100 kg . Part 2 : Clinical diagnosis probable AD accord NINCDSADRDA criterion . Part 2 : Manifestation AD symptom least 6 month randomization . Part 1 : History presence psychiatric disease/condition , GI , renal , hepatic , cardiovascular , psychiatric , retinal disease disorder . Part 2 : Significant disease affect CNS Alzheimer 's disease , include limited dementia , significant neurological major psychiatric disease . History use antipsychotic drug , chronic use antidepressant anxiolytic drug . Frequent use ( 2 day per week last 12 week ) tobacco nicotine product . History neurological disease , include seizure , recent memory impairment , clinically significant head injury .</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>AZD3293</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>Elderly volunteer</keyword>
	<keyword>Alzheimer 's Disease patient</keyword>
	<keyword>AD patient</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Multiple Ascending Dose Study</keyword>
</DOC>